Skip to main content
Erschienen in: International Journal of Clinical Oncology 11/2019

26.06.2019 | Original Article

Development and validation of a nomogram containing the prognostic determinants of chondrosarcoma based on the Surveillance, Epidemiology, and End Results database

verfasst von: Jun Zhang, Zhenyu Pan, Fanfan Zhao, Xiaojie Feng, Yuanchi Huang, Chuanyu Hu, Yuanjie Li, Jun Lyu

Erschienen in: International Journal of Clinical Oncology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to develop and validate a reliable nomogram for predicting the disease-specific survival (DSS) of chondrosarcoma patients.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database was queried from 2004 to 2015 to identify cases of histologically confirmed chondrosarcoma. Multivariate Cox regression analysis was performed to identify independent prognostic factors and construct a nomogram for predicting the 3- and 5-year DSS rates. Predictive values were compared between the new model and the American Joint Committee on Cancer (AJCC) staging system using concordance indexes (C-indexes), calibration plots, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA).

Results

Multivariate Cox regression identified 1180 patients, who were used to establish a nomogram based on a new model containing the predictive variables of age, socioeconomic status, tumor size, surgery status, chemotherapy status, and AJCC staging. In the nomogram, age at diagnosis is the factor with the highest risk, followed by AJCC stage IV and tumor size > 100 mm. Both the C-index and the calibration plots demonstrated the good performance of the nomogram. Moreover, both NRI and IDI were improved compared to the AJCC staging system, and also DCA demonstrated that the nomogram is clinically useful.

Conclusion

We have developed a reliable nomogram for determining the prognosis and treatment outcomes of chondrosarcoma patients that is superior to the traditional AJCC staging system.
Literatur
3.
Zurück zum Zitat Giuffrida AY, Burgueno JE, Koniaris LG, et al.: Chondrosarcoma in the United States (1973–2003): an analysis of 2890 cases from the SEER database. J Bone Jt Surg Am Vol 91(5), 1063–1072. doi: 10.2106/JBJS.H.00416. Giuffrida AY, Burgueno JE, Koniaris LG, et al.: Chondrosarcoma in the United States (1973–2003): an analysis of 2890 cases from the SEER database. J Bone Jt Surg Am Vol 91(5), 1063–1072. doi: 10.2106/JBJS.H.00416.
4.
Zurück zum Zitat Larsson SE, Lorentzon R (1974) The geographic variation of the incidence of malignant primary bone tumors in Sweden. The Journal of bone and joint surgery American 56(3):592–600CrossRef Larsson SE, Lorentzon R (1974) The geographic variation of the incidence of malignant primary bone tumors in Sweden. The Journal of bone and joint surgery American 56(3):592–600CrossRef
9.
Zurück zum Zitat Kang JS, Lee S, Son D et al (2018) Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system. J Hepatobiliary Pancreat Sci 25(2):124–130. https://doi.org/10.1002/jhbp.520 CrossRefPubMed Kang JS, Lee S, Son D et al (2018) Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system. J Hepatobiliary Pancreat Sci 25(2):124–130. https://​doi.​org/​10.​1002/​jhbp.​520 CrossRefPubMed
13.
Zurück zum Zitat Arshi A, Sharim J, Park DY, et al. (2017) Chondrosarcoma of the Osseous spine: an analysis of epidemiology, patient outcomes, and prognostic factors using the SEER Registry from 1973 to 2012. Spine (Phila Pa 1976) 42(9): 644–652. doi:10.1097/BRS.0000000000001870. Arshi A, Sharim J, Park DY, et al. (2017) Chondrosarcoma of the Osseous spine: an analysis of epidemiology, patient outcomes, and prognostic factors using the SEER Registry from 1973 to 2012. Spine (Phila Pa 1976) 42(9): 644–652. doi:10.1097/BRS.0000000000001870.
14.
Zurück zum Zitat Song K, Song J, Shi X, et al. (2018) Development and validation of nomograms predicting overall and cancer-specific survival of spinal chondrosarcoma patients. Spine (Phila Pa 1976) 43(21): E1281–E1289. doi:10.1097/BRS.0000000000002688. Song K, Song J, Shi X, et al. (2018) Development and validation of nomograms predicting overall and cancer-specific survival of spinal chondrosarcoma patients. Spine (Phila Pa 1976) 43(21): E1281–E1289. doi:10.1097/BRS.0000000000002688.
19.
Zurück zum Zitat Duchman KR, Gao YN, Miller BJ (2015) Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 39(4):593–599CrossRef Duchman KR, Gao YN, Miller BJ (2015) Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 39(4):593–599CrossRef
20.
23.
Zurück zum Zitat Biermann JS, Chow W, Reed DR et al (2017) NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Canc Netw 15(2):155–167CrossRef Biermann JS, Chow W, Reed DR et al (2017) NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Canc Netw 15(2):155–167CrossRef
32.
Zurück zum Zitat Asuncion Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldan V et al (2017) Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. Thromb Haemost 117(10):1848–1858. https://doi.org/10.1160/TH17-07-0478 CrossRef Asuncion Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldan V et al (2017) Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. Thromb Haemost 117(10):1848–1858. https://​doi.​org/​10.​1160/​TH17-07-0478 CrossRef
33.
Zurück zum Zitat Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V et al (2017) Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia atrial fibrillation project. Thromb Haemost 117(10):1848–1858. https://doi.org/10.1160/TH17-07-0478 CrossRefPubMed Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V et al (2017) Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia atrial fibrillation project. Thromb Haemost 117(10):1848–1858. https://​doi.​org/​10.​1160/​TH17-07-0478 CrossRefPubMed
38.
Metadaten
Titel
Development and validation of a nomogram containing the prognostic determinants of chondrosarcoma based on the Surveillance, Epidemiology, and End Results database
verfasst von
Jun Zhang
Zhenyu Pan
Fanfan Zhao
Xiaojie Feng
Yuanchi Huang
Chuanyu Hu
Yuanjie Li
Jun Lyu
Publikationsdatum
26.06.2019
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 11/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01489-9

Weitere Artikel der Ausgabe 11/2019

International Journal of Clinical Oncology 11/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.